| Literature DB >> 15734039 |
Loïc Faye1, Aurelia Boulaflous, Meriem Benchabane, Véronique Gomord, Dominique Michaud.
Abstract
Plants have become, over the last ten years, a suitable alternative to microbial and animal cell factories for the production of clinically-useful, therapeutic proteins. Besides the well known advantage of low-cost and large-scale production of safe and biologically active mammalian proteins, plants also are able to perform most post-translational maturations required for biological activity and suitable pharmacokinetics of recombinant therapeutic proteins. In this short review we focus on glycosylation and proteolytic processing of plant-made pharmaceuticals during their transport through the plant cell's secretory pathway. We also address the practical implications of these important processes on the effectiveness of plant molecular pharming systems.Entities:
Mesh:
Substances:
Year: 2005 PMID: 15734039 DOI: 10.1016/j.vaccine.2004.11.003
Source DB: PubMed Journal: Vaccine ISSN: 0264-410X Impact factor: 3.641